Combination immunotherapies for type 1 diabetes mellitus.
about
Efficient Software for Multi-marker, Region-Based Analysis of GWAS Data.Targeting innate immunity to downmodulate adaptive immunity and reverse type 1 diabetes.The Soybean Peptide Vglycin Preserves the Diabetic β-cells through Improvement of Proliferation and Inhibition of Apoptosis.Animal models of human type 1 diabetes for evaluating combination therapies and successful translation to the patient with type 1 diabetes.Combinatorial drug delivery approaches for immunomodulation.Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus.Bone health in subjects with type 1 diabetes for more than 50 years.Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S).Adult-onset autoimmune diabetes: current knowledge and implications for management.An editorial on the article 'Patents in the Diabetes Area in the Years 2008-2016'.Effect of GLP-1 and GIP on C-peptide secretion after glucagon or mixed meal tests: Significance in assessing B-cell function in diabetes.Recognizing Presymptomatic Type 1 Diabetes in the Workplace.Pharmacological Treatment in Diabetes Mellitus Type 1 - Insulin and What Else?DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.Inhibition of TBK1/IKKε Promotes Regeneration of Pancreatic β-cellsChanging perspectives on the progression of type 1 diabetes
P2860
Q31044244-E5E2BA45-B038-4276-803F-CB4E5815CBC0Q33739020-0842F1F7-219B-4302-90CC-1F9BB15B5326Q36221646-64CECF55-B5C4-47CC-8EBA-2D12F8C28BF5Q38660322-03B9C45B-0DF1-4F1C-AD1B-C7F2452D2F4EQ38680602-C47CFFC5-8C1D-41FA-ABCD-EAC35734F525Q38825378-7DFFB21B-2A44-42FC-91C8-C58E93330414Q38943012-06221F6E-6C09-4B6A-A368-A18307431269Q42371744-3926606F-4003-4887-91BF-E7D825828974Q47694295-28DC7DDB-68DD-4A9B-B61A-EECEF12DF310Q47732022-C3C4DB1E-C277-41F9-8FD2-366FC0A6204CQ48329552-32AA08DD-2F66-458F-8CDE-96CADBD03D3AQ50106547-4E10702B-4454-442B-80C8-999C4C13BB05Q52562630-CCB22DD2-E8E0-4FC6-8DD4-432AD9796F4FQ55048866-00EB6AA9-8BB7-473E-B84E-374D17724BC7Q57805706-B7E1A388-D418-4CA9-8487-E7EF2658B817Q57917243-18109F79-DCAA-4786-993F-2AF46327836C
P2860
Combination immunotherapies for type 1 diabetes mellitus.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Combination immunotherapies for type 1 diabetes mellitus.
@en
type
label
Combination immunotherapies for type 1 diabetes mellitus.
@en
prefLabel
Combination immunotherapies for type 1 diabetes mellitus.
@en
P2860
P50
P356
P1476
Combination immunotherapies for type 1 diabetes mellitus.
@en
P2860
P2888
P304
P356
10.1038/NRENDO.2015.8
P577
2015-02-17T00:00:00Z